Dear Ms. Seymour:

Please refer to your Biologics License Application (BLA) submitted and received on December 18, 2019 under section 351(a) of the Public Health Service Act (PHS Act) for lisocabtagene maraleucel.

**LICENSING**

We are issuing Department of Health and Human Services U.S. License No. 2156 to Juno Therapeutics, Inc., Seattle, Washington, under the provisions of section 351(a) of the PHS Act controlling the manufacture and sale of biological products. The license authorizes you to introduce or deliver for introduction into interstate commerce, those products for which your company has demonstrated compliance with establishment and product standards.

Under this license, you are authorized to manufacture the product lisocabtagene maraleucel, which is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. Lisocabtagene maraleucel is not indicated for the treatment of patients with primary central nervous system (CNS) lymphoma.

The review of this product was associated with the following National Clinical Trial (NCT) numbers: NCT02631044; NCT03484702; NCT03744676; NCT03310619; NCT03483103; NCT03331198; NCT03743246; and NCT03435796.

**MANUFACTURING LOCATIONS**

Under this license, you are approved to manufacture lisocabtagene maraleucel at your facility located at 1522 217th Pl. SE Bothell, WA 98021. The bulk lentiviral vector will be
You may label your product with the proprietary name BREYANZI and market it in 5 mL single-use vials containing an extractable volume of 4.6 mL at a concentration of $1.5 \times 10^6$ to $70 \times 10^6$ CAR-positive viable T cells per mL, for each of the CD4 and CD8 Drug Products. One to four vials each of CD4 and CD8 Drug Products will be supplied for the dose of $50 \times 10^6$ – $110 \times 10^6$ CAR-positive T cells.

**ADVISORY COMMITTEE**

We did not refer your application to an Advisory Committee because our review of information submitted in your BLA, including the clinical study design and trial results, did not raise concerns or controversial issues that would have benefited from an advisory committee discussion.

**DATING PERIOD**

The dating period for lisocabtagene maraleucel shall be 13 months from the date of manufacture when stored at $\leq -130^\circ C$. The date of manufacture shall be defined as the date of final formulation of the drug product. The dating period for the lentiviral vector shall be (b) (4) when stored at (b) (4). We have approved the stability protocols in your license application for the purpose of extending the expiration dating period of your lentiviral vector and drug product under 21 CFR 601.12.

**FDA LOT RELEASE**

You are not currently required to submit samples or protocols of future lots of lisocabtagene maraleucel to the Center for Biologics Evaluation and Research (CBER) for release by the Director, CBER, under 21 CFR 610.2(a). We will continue to monitor compliance with 21 CFR 610.1 requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

**BIOLOGICAL PRODUCT DEVIATIONS**

You must submit reports of biological product deviations under 21 CFR 600.14. You should identify and investigate all manufacturing deviations promptly, including those associated with processing, testing, packaging, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to the Director, Office of Compliance and Biologics Quality, at the following address:
MANUFACTURING CHANGES

You must submit information to your BLA for our review and written approval under 21 CFR 601.12 for any changes in, including but not limited to, the manufacturing, testing, packaging or labeling of lisocabtagene maraleucel or in the manufacturing facilities.

LABELING

Under 21 CFR 201.57(c)(18), patient labeling must be referenced in section 17 PATIENT COUNSELING INFORMATION. Patient labeling must be available and may either be reprinted immediately following the full prescribing information of the package insert or accompany the prescription product labeling.

We hereby approve the draft package insert labeling submitted under amendment 103, dated February 3, 2021 and the draft carton and container labeling submitted under amendment 81, dated October 28, 2020.

WAIVER OF HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.
PACKAGE AND CONTAINER LABELS

Please electronically submit final printed package and container labels that are identical to the package and container labels submitted on February 3, 2021 and October 28, 2020, according to the guidance for industry Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications at https://www.fda.gov/downloads/drugs/guidancecompliance/regulatoryinformation/guidances/ucm333969.pdf.

All final labeling should be submitted as Product Correspondence to this BLA STN 125714 at the time of use (prior to marketing) and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71-G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

ADVERSE EVENT REPORTING

You must submit adverse experience reports in accordance with the adverse experience reporting requirements for licensed biological products (21 CFR 600.80) and you must submit distribution reports as described in 21 CFR 600.81. For information on adverse experience reporting, please refer to the guidance for industry Providing Submissions in Electronic Format — Postmarketing Safety Reports at https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm458559.pdf and FDA’s Adverse Event reporting System website at
PEDIATRIC REQUIREMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because the biological product for this indication has an orphan drug designation, you are exempt from this requirement.

POSTMARKETING REQUIREMENTS UNDER SECTION 505(o)

Section 505(o) of the Federal Food, Drug, and Cosmetic Act (FDCA) authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute (section 505(o)(3)(A), 21 U.S.C. 355(o)(3)(A)).

We have determined that an analysis of spontaneous postmarketing adverse events reported under section 505(k)(1) of the FDCA will not be sufficient to identify a serious risk of secondary malignancies associated with use of lisocabtagene maraleucel.

Furthermore, the pharmacovigilance system that FDA is required to maintain under section 505(k)(3) of the FDCA is not sufficient to assess this serious risk.

Therefore, based on appropriate scientific data, we have determined that you are required to conduct the following study:

1. A post-marketing multicenter, prospective, observational study to assess the long-term safety of lisocabtagene maraleucel and the risk of secondary malignancies occurring after treatment with lisocabtagene maraleucel. The study will include at least 1500 adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy; the enrolled patients will be followed for 15 years after the product administration.

We acknowledge the timetable you submitted on January 19, 2021, which states that you will conduct this study according to the following schedule:

Final Protocol Submission: February 28, 2021
Study Completion Date: April 30, 2041

Final Report Submission: July 31, 2042

Please submit the protocol to your IND 16506, with a cross-reference letter to this BLA 125714 explaining that this protocol was submitted to the IND. Please refer to the sequential number for each study/clinical trial and the submission number as shown in this letter.

Please submit final study reports to the BLA. If the information in the final study report supports a change in the labeling, the final study report must be submitted as a supplement to this BLA 125714. For administrative purposes, all submissions related to this postmarketing study required under section 505(o) must be submitted to this BLA and be clearly designated as:

- Required Postmarketing Correspondence under Section 505(o)
- Required Postmarketing Final Report under Section 505(o)
- Supplement contains Required Postmarketing Final Report under Section 505(o)

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. In addition, section 506B of the FDCA and 21 CFR 601.70 require you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

You must describe the status in an annual report on postmarketing studies for this product. Label your annual report as an **Annual Status Report of Postmarketing Requirements/Commitments** and submit it to the FDA each year within 60 calendar days of the anniversary date of this letter until all Requirements and Commitments subject to the reporting requirements of section 506B of the FDCA are fulfilled or released. The status report for each study should include:

- the sequential number for each study as shown in this letter;
- information to identify and describe the postmarketing requirement;
- the original milestone schedule for the requirement;
- the revised milestone schedule for the requirement, if appropriate;
- the current status of the requirement (i.e., pending, ongoing, delayed, terminated, or submitted); and,
- an explanation of the status for the study or clinical trial. The explanation should include how the study is progressing in reference to the original projected schedule, including, the patient accrual rate (i.e., number enrolled to date and the total planned enrollment).
As described in 21 CFR 601.70(e), we may publicly disclose information regarding these postmarketing studies on our website at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Post-marketingPhaseIVCommitments/default.htm.

We will consider the submission of your annual report under section 506B of the FDCA and 21 CFR 601.70 to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in section 505(o) and 21 CFR 601.70. We remind you that to comply with section 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to periodically report on the status of studies or clinical trials required under section 505(o) may be a violation of FDCA section 505(o)(3)(E)(ii) and could result in regulatory action.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We acknowledge your written commitment as described in submission number 0064 (dated August 20, 2020) as outlined below:

1. Juno Therapeutics, Inc., commits to prospectively validate the per protocol (b) (4) and will provide the validation report.

   Final Report Submission: September 30, 2021

We request that you submit information concerning nonclinical and chemistry, manufacturing, and control postmarketing commitments and final reports to your BLA 125714. Please refer to the sequential number for each commitment. Please use the following designators to prominently label all submissions, including supplements, relating to these postmarketing study commitments as appropriate:

- Postmarketing Commitment – Status Update
- Postmarketing Commitment – Final Study Report
- Supplement contains Postmarketing Commitment – Final Study Report

For each postmarketing commitment not subject to the reporting requirements of 21 CFR 601.70, you may report the status to FDA as a Postmarketing Commitment – Status Update. The status report for each commitment should include:

- the sequential number for each study as shown in this letter;
- the submission number associated with this letter;
- describe what has been accomplished to fulfill the non-section 506B PMC; and,
- summarize any data collected or issues with fulfilling the non-section 506B PMC.
When you have fulfilled your commitment, submit your final report as Postmarketing Commitment – Final Study Report or Supplement contains Postmarketing Commitment – Final Study Report.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

Section 505-1 of the FDCA authorizes FDA to require the submission of a risk evaluation and mitigation strategy (REMS), if FDA determines that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks [section 505-1(a)].

In accordance with section 505-1 of FDCA, we have determined that a REMS is necessary for BREYANZI to ensure the benefits of the drug outweigh the risks of cytokine release syndrome (CRS) and neurological toxicities.

Your proposed REMS must include the following:

**Elements to assure safe use:** Pursuant to 505-1(f)(1), we have determined that BREYANZI can be approved only if elements necessary to assure safe use are required as part of the REMS to mitigate the risks of CRS and neurological toxicities.

Your REMS includes the following elements to mitigate these risks:

- Health care settings that dispense BREYANZI are specially certified;
- BREYANZI is dispensed to patients only in certain health care settings.

**Implementation System:** The REMS must include an implementation system to monitor and evaluate the implementation of the elements to assure safe use (outlined above) which require health care settings that dispense the drug be specially certified and the drug be dispensed to patients only in certain health care settings, specifically, certified hospitals and their associated clinics with appropriate access to tocilizumab. The implementation system should also include an intervention plan to address any findings of non-compliance with elements to assure safe use and to address any findings that suggest an increase in risk to patients.

Your proposed REMS, submitted on November 16, 2020, and appended to this letter, is approved. The REMS consists of elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS.

The REMS assessment plan must include, but is not limited to, the following:

For the first (6-month) BREYANZI REMS assessment only, provide the following operational metrics:

A. Date the BREYANZI REMS website went live;
B. Date the REMS call center was operational;
C. Date hospitals were able to complete the BREYANZI REMS certification
D. Date of first notification of hospital and their associated clinic certification.

For the 12-month and subsequent annual assessments:

The REMS Program Infrastructure and Performance (provide in tabular format as appropriate):

A. Hospitals and their associated clinics enrollment and education statistics (provide for each reporting period and cumulatively)

- List of all enrolled hospital sites, locations, dates of enrollment, and method (email, fax) of enrollment and dates of certification notification;
- Number of incomplete enrollments at the time of assessment data lock;
- Number, format, and date of training on BREYANZI REMS;
- Number of knowledge assessments completed by hospital and their personnel, other than the authorized representative, by certified hospital;
- Mean and range of attempts to successfully complete the knowledge assessment;
- Summary of most frequently missed questions;
- Number of hospitals that require retraining due to the absence of any BREYANZI dispensing at least once annually from the date of certification in the BREYANZI REMS.

B. Utilization of BREYANZI

- Number of BREYANZI shipments sent to BREYANZI Certified Care Centers;
- Number of unique patients treated with BREYANZI, stratified by BREYANZI Certified Care Center type; include age and gender for treated patients;
- Number and age of patients for which BREYANZI was ordered but never infused and the reason(s) that the patient was not treated
  - provide number of occurrences at each certified hospital for each reporting period and cumulatively;
- Time between certification and first order for BREYANZI for each hospital certified during the assessment period.

C. Compliance with BREYANZI REMS

- Number and name of non-certified hospital(s) that have treated a patient with BREYANZI and any corrective actions taken to prevent future occurrences (e.g., provision of REMS training program, REMS hospital certification form) and the number of these that subsequently became certified (current reporting period and cumulative);
• Audits: A summary of findings from first-order audits and annual audits (current reporting period) by type of audit deficiencies and stratified by type of center (i.e., clinic or hospital);
• Summary report of all non-compliance, associated corrective and preventative actions (CAPA), and the status of CAPA plans.

D. BREYANZI REMS Customer Care Center

• Number of contacts by stakeholder type (patient/guardian, prescriber, hospital and their associated clinic authorized representative, other health care provider (HCP), other) and reason for the call;
• Summary of frequently asked questions (FAQ) by stakeholder type;
• A description of each call, including stakeholder type, that may indicate an issue with access, burden, or an adverse event;
• A summary of corrective actions resulting from issues identified;
• Summary of any non-compliance that is identified through call center contacts, source of report and resulting corrective and preventative actions.

E. An evaluation of understanding of the risks and mitigation strategies of the BREYANZI REMS as well as compliance with the mitigation strategies in those who prescribe, dispense, or administer BREYANZI as well as hospital and their associated clinic authorized representatives.

F. With respect to each goal included in the strategy, an assessment of the extent to which the approved strategy, including each element of the strategy, is meeting the goal or whether one or more such goals or such elements should be modified (Section 505-1(g)(3).

Knowledge, Attitudes, and Behavior (KAB) surveys will be conducted with those who prescribe, dispense, or administer BREYANZI, as well as hospital authorized representatives, in order to assess their awareness and understanding of the risks of BREYANZI and the mitigation strategies as outlined in the REMS goals and objectives.

The methodology and the knowledge, attitudes, and behavior (KAB) protocols and survey instruments should be submitted to the Agency for review at least 90 days before the surveys are initially administered.

The requirements for assessments of an approved REMS under section 505-1(g)(3) include with respect to each goal included in the strategy, an assessment of the extent to which the approved strategy, including each element of the strategy, is meeting the goal or whether 1 or more such goals or such elements should be modified.

We remind you that in addition to the REMS assessments submitted according to the timetable in the approved REMS, you must include an adequate rationale to support a
proposed REMS modification for the addition, modification, or removal of any goal or element of the REMS, as described in section 505-1(g)(4) of the FDCA.

We also remind you that you must submit a REMS assessment when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A). This assessment should include:

- An evaluation of how the benefit-risk profile will or will not change with the new indication;
- A determination of the implications of a change in the benefit-risk profile for the current REMS;
- If the new, proposed indication for use introduces unexpected risks: A description of those risks and an evaluation of whether those risks can be appropriately managed with the currently approved REMS.
- If a REMS assessment was submitted in the 18 months prior to submission of the supplemental application for a new indication for use: A statement about whether the REMS was meeting its goals at the time of the last assessment and if any modifications of the REMS have been proposed since that assessment.
- If a REMS assessment has not been submitted in the 18 months prior to submission of the supplemental application for a new indication for use: Provision of as many of the currently listed assessment plan items as is feasible.
- If you propose a REMS modification based on a change in the benefit-risk profile or because of the new indication of use, submit an adequate rationale to support the modification, including: Provision of the reason(s) why the proposed REMS modification is necessary, the potential effect on the serious risk(s) for which the REMS was required, on patient access to the drug, and/or on the burden on the health care delivery system; and other appropriate evidence or data to support the proposed change. Additionally, include any changes to the assessment plan necessary to assess the proposed modified REMS.
- If you are not proposing a REMS modification, provide a rationale for why the REMS does not need to be modified.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:
UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT METHODOLOGY)

Prominently identify any submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**BLA 125714 REMS ASSESSMENT**

or

**NEW SUPPLEMENT FOR BLA 125714 CHANGES BEING EFFECTED IN 30 DAYS PROPOSED MINOR REMS MODIFICATION**

or

**NEW SUPPLEMENT FOR BLA 125714 PRIOR APPROVAL SUPPLEMENT PROPOSED MAJOR REMS MODIFICATION**

or

**NEW SUPPLEMENT FOR BLA 125714 PRIOR APPROVAL SUPPLEMENT PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABEL CHANGES SUBMITTED IN SUPPLEMENT [125714/####]**

or

**NEW SUPPLEMENT (NEW INDICATION FOR USE) FOR BLA 125714 REMS ASSESSMENT PROPOSED REMS MODIFICATION (if included)**

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:

**REMS REVISION FOR BLA 125714**

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word format. If certain documents, such as enrollment forms, are only in PDF format, they may be submitted as such, but the preference is to include as many as possible in Word format.
FDA can accept the REMS document in Structured Product Labeling (SPL) format. If you intend to submit the REMS document in SPL format, as soon as possible, but no later than 14 days from the date of this letter, submit the REMS document in SPL format using the FDA automated drug registration and listing system (eLIST).

POST-APPROVAL FEEDBACK MEETING

New biological products qualify for a post-approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, please contact the Regulatory Project Manager for this application.

Sincerely,

Mary A. Malarkey
Director
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research

Wilson W. Bryan, MD
Director
Office of Tissues and Advanced Therapies Center for Biologics Evaluation and Research

Enclosures:
REMS